CheckMate 651 is a phase III, randomized, multicenter trial studying nivolumab in combination with ipilimumab, a CTLA-4 inhibitor, versus EXTREME as first-line therapy in R/M HNSCC (NCT02741570). This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.